Twenty-one subjects formed a trekking expedition to study the effects of acetazolamide on exercise performance and acclimatization at high altitude. Subjects were randomized to acetazolamide or placebo on a double blind basis. During ascent to and stay for 6 nights at 4846 m studies were carried out on blood gases, 2,3 diphosphoglycerate (2,3 DPG), proteinuria, exercise testing, intestinal absorption, purine metabolism and changes in body composition. The results showed beneficial effects of acetazolamide on exercise performance and preservation of muscle mass.
Introduction
The Birmingham Medical Research Expeditionary Society (BMRES) was formed in 1977 by a group of doctors and scientists at Birmingham University to investigate aspects of mountain medicine.' Since then the Society have carried out four major expeditions culminating in the 1984 expedition to Nepal, the results ofwhich are the subject ofthis symposium. The earlier investigations included the use of acetazolamide2 and methazolamide3 for prophylaxis of acute mountain sickness and the assessment of proteinuria at high altitude. 4 The results have encouraged the use of acetazolamide, particularly amongst trekkers, on the world's highest mountains and has probably increased the safety and enjoyment of mountain travel.
However, opinions on acetazolamide have not been entirely favourable and there has been little enthusiasm for its use amongst climbers. This is for several reasons. First, there have been no satisfactory studies of the drug in acclimatized subjects at high altitude. Whilst trekkers may benefit from its use when ascending rapidly, climbers tend to ascend more slowly in order to acclimatize, which might render the drug less appropriate. Second, it is not known whether acetazolamide adversely affects exercise at altitude. Since there is evidence that sea level exercise is reduced by acetazolamide' similar findings at high altitude would be of great concern. Other objections include side effects (although the drug does have an excellent safety record) and moral attitudes. The answer to these depends upon circumstances; the balance of advantages and disadvantages and the mountain dangers involved.
The purpose of our recent expedition was to collect relevant data and thereby allow us to make a recommendation as to the value of acetazolamide for climbers. Our results were presented at this symposium.
The Expedition
The group comprised 19 men and 2 women (aged 22 to 56), twelve of whom were medically qualified. All normally resided at less than 200 m and none had been to high altitude in the previous 6 months. All were in good general health. After a flight to Katmandu in Nepal at 1300 m the group walked for 11 days from Gorka to Rupina La at 4846 m (see Figure 1) . They stayed at this height for 6 days (eight subjects ascended to 5700 m during one day) and then descended rapidly to Katmandu. Ascent was gradual to minimize the symptoms of acute mountain sickness (AMS) and allow good acclimatization (Figure 2 ).
Subjects were randomized by an independent observer to acetazolamide or placebo groups using stratification by age or sex. All subjects took acetazolamide for 48 assessment and peer review score.' Two subjects descended prematurely from 4500 m (the ninth day); one was suffering from severe headaches which stopped after descending (presumably AMS); the second had bronchitis whilst a third person was well but assisted the others to the nearest town. Two of the three rejoined the group 3 days later at the top camp. Many subjects suffered from minor colds and coughs during the early and middle part of the expedition and many received antibiotics. Few subjects had gastrointestinal disturbances. This low incidence was possibly attributable to the use of iodine in all drinking water. 
